



Contact: Julie Bryant  
VP Business Development and Marketing  
GeneGo, Inc.  
(858) 756 7996  
julie@genego.com

## GENEGO LICENSES METACORE TO EXELIXIS

St. Joseph, Michigan, May 13th, 2005 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Exelixis has licensed MetaCore™, GeneGo's platform for mining of high-throughput experimental data in the context of biological networks, pathways and human diseases. Among other features, MetaCore has built manually curated proprietary database of transcriptional factors and receptors supported by unique network algorithms enabling reconstruction of full length regulatory pathways. This allows users to investigate all the genes that regulate a specific gene or a group of genes at the transcription level or build transcriptional regulation networks characteristic for particular diseases and other conditions.

“Exelixis is renowned for its powerful, fully integrated discovery platform that is capable of high-throughput target identification and validation. This has been applied to develop high-quality, differentiated pharmaceutical compounds for the potential treatment of cancer and metabolic diseases in collaborations with top pharmaceutical companies”, said Julie Bryant, VP of business development at GeneGo. “We are very pleased that Exelixis chose MetaCore™ to assist their discovery endeavors.”

### About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at [www.genego.com](http://www.genego.com).

MetaCore™ and MetaDrug™ are trademarks of GeneGo, Inc.